New Cytometry Dataset Reveals Drivers of Immune Checkpoint Inhibitor Adverse Events

We're making available a 43-marker mass cytometry dataset we created from 70 PBMC specimens collected across 28 melanoma patients at the Huntsman Cancer Institute. This dataset gives you a detailed real-world look at how immune responses connect to immune-related adverse events (irAEs) during checkpoint inhibitor therapy.

Why this matters

Immune checkpoint inhibitors have reshaped cancer treatment, but irAEs remain a major barrier to patient safety and trial success. By making this dataset public, we’re enabling researchers and developers to investigate predictive biomarkers of toxicity, knowledge that can inform trial design, improve patient monitoring, and ultimately make immunotherapy safer and more effective.

Dataset Featured in the News 

This data formed the basis of our recent co-publication in the Journal for ImmunoTherapy of Cancer (Kovacsovics-Bankowski et al., 2024), which identified key immune features associated with severe irAEs, including:

• Higher baseline CD4⁺ naïve T cells and lower CD16⁺ NK cells, predicting severe irAEs.
• Reduced TIGIT⁺ regulatory T cells, suggesting weaker immune regulation before treatment.
• Activation of CD4⁺ and CD8⁺ central memory T cells at peak toxicity, highlighting mechanisms of off-target immune activation. 

‍

Available today!  

We’ve made this resource available so you can access real-world, high-dimensional immune profiling data that accelerates biomarker discovery and helps you make faster, more confident development decisions.

Explore the dataset now at app.teiko.bio (HCI001)